These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology. Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805 [TBL] [Abstract][Full Text] [Related]
29. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341 [TBL] [Abstract][Full Text] [Related]
31. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852 [TBL] [Abstract][Full Text] [Related]
33. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320 [TBL] [Abstract][Full Text] [Related]
34. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Phan SI; Chen Z; Xu P; Li Z; Gao X; Foster SL; Teng MN; Tripp RA; Sakamoto K; He B Vaccine; 2014 May; 32(25):3050-7. PubMed ID: 24717150 [TBL] [Abstract][Full Text] [Related]
35. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Jones BG; Sealy RE; Surman SL; Portner A; Russell CJ; Slobod KS; Dormitzer PR; DeVincenzo J; Hurwitz JL Vaccine; 2014 May; 32(26):3264-73. PubMed ID: 24721531 [TBL] [Abstract][Full Text] [Related]
36. A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection. Endt K; Wollmann Y; Haug J; Bernig C; Feigl M; Heiseke A; Kalla M; Hochrein H; Suter M; Chaplin P; Volkmann A Front Immunol; 2022; 13():841471. PubMed ID: 35774800 [TBL] [Abstract][Full Text] [Related]